Amelioration of Alzheimer's disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer's disease.

Neural Regen Res · 2019 · PMC6425849 · PMID 30804241

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Also there may be significant differences between early-onset (familial) and late-onset (sporadic) AD such that treatments tested in existing models may be useful for early-onset AD but not for late-onset AD which is more common in human patients (Onos et al., 2016).

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.